Tilray | TRLY - Sales Revenues

Stock Price
1.53
Daily Change
-0.11 -6.71%
Monthly
20.47%
Yearly
-34.05%
Q3 Forecast
1.63

Tilray reported $308.01M in Sales Revenues for its fiscal quarter ending in June of 2025.



Financials
Stock Price USD
Assets USD 4.19B
Cash and Equivalent USD 189.7M
Cost of Sales USD 149.73M
Current Assets USD 707.34M
Current Liabilities USD 278.52M
Debt USD 351.72M
EBIT USD -42.22M
EBITDA USD -101K
Employees USD 2.65K
EPS Earnings Per Share USD -1.78
Equity Capital and Reserves USD 3.47B
Gross Profit on Sales USD 61.22M
Interest Expense on Debt USD 7.77M
Interest Income USD 12.83M
Loan Capital USD 316.63M
Market Capitalization USD 1.18B
Net Income USD -85.34M
Operating Expenses USD 253.17M
Operating Profit USD -42.22M
Ordinary Share Capital USD 93K
Pre-Tax Profit USD -83.24M
Sales Revenues USD 308.01M
Selling and Administration Expenses USD 72.38M
Stock USD 266.01M
Trade Creditors USD 99.08M
Trade Debtors USD 112.74M

Sales Change Date
Acasti Pharma USD -4760000 4.76M Dec/2024
Alaunos Therapeutics USD 0 4K Sep/2024
Aurora Cannabis CAD 98.02M 9.82M Jun/2025
Avita Medical AUD 18.41M 7.89M Dec/2024
Canopy Growth CAD 72.13M 2.63M Jun/2025
Cronos Group USD 33.46M 160K Jun/2025
Dianthus Therapeutics USD 193K 1.13M Jun/2025
Divis Laboratories Ltd 24.1B 1.75B Jun/2025
Ionis Pharmaceuticals USD 452M 320M Jun/2025
IQVIA Holdings USD 4.02B 190M Jun/2025
Knight Therapeutics CAD 92.26M 3.31M Sep/2024
Moderna USD 142M 34M Jun/2025
Organigram Holdings CAD 70.79M 28.06M Jun/2025
Organon & Co USD 1.59B 80M Jun/2025
Revvity USD 720M 55M Jun/2025
Tectonic Therapeutic USD 0 0 Dec/2024
Tilray USD 308.01M 43.78M Jun/2025
Viatris USD 3.57B 320M Jun/2025
Xeris Pharmaceuticals USD 71.54M 11.44M Jun/2025